- Lipid Disorders in Children and Adolescents: Screening
- Author:United States Preventive Services Task Force (USPSTF)
- Published:July 2023
- Implementing Strategies to Prevent Infections in Acute-Care Settings
- Author:Infectious Diseases Society of America (IDSA); Society for Healthcare Epidemiology of America America (SHEA)
- Published:July 11, 2023
- Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
- Author:American Society of Clinical Oncology (ASCO)
- Published:July 17, 2023
- Management of Patients with Chronic Coronary Disease
- Author:American College of Cardiology (ACC); American Heart Association (AHA)
- Published:July 20, 2023
- CYP3A4 and CYP3A5 Genotyping Recommendations
- Society:Association for Molecular Pathology (AMP); College of American Pathologists (CAP)
- Published:July 5, 2023
- Management of Posttraumatic Stress Disorder and Acute Stress Disorder
- Society:Veterans Health Administration / Department of Defense (VA/DoD)
- Published:July 1, 2023
- Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
- Society:American Association for Clinical Chemistry (AACC); American Diabetes Association (ADA)
- Published:July 20, 2023
- Endoscopic Submucosal Dissection for the Management of Early Esophageal and Gastric Cancers
- Society:American Society for Gastrointestinal Endoscopy (ASGE)
- Published:July 25, 2023
- Stage III Non-Small Cell Lung Cancer
- Society:American Society of Clinical Oncology (ASCO)
- Published:July 20, 2023
- Treatment of Antimicrobial Resistant Gram-Negative Infections
- Society:Infectious Diseases Society of America (IDSA)
- Published:June 7, 2023
- Management of Cancer Cachexia
- Society:American Society of Clinical Oncology (ASCO)
- Published:July 12, 2023
- Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Society:American Society of Clinical Oncology (ASCO)
- Published:July 11, 2023
- Stage IV Non-Small Cell Lung Cancer with Driver Alterations
- Society:American Society of Clinical Oncology (ASCO)
- Published:July 11, 2023
- Leqvio (Novartis)Expanded Indication
- To include treatment of adults with high LDL-C and who are at increased risk of heart disease.
- Liletta (Medicines360)
- Treatment of Heavy Menstrual Bleeding (HMB) for up to five years in patients who choose intrauterine contraception as their method of contraception.
- Opill (Perrigo) New Over-the-Counter
- For over-the-counter (OTC) use for all ages.
- Veklury (Gilead)
- In COVID-19 patients with severe renal impairment, including those on dialysis.
- Beyfortus (AstraZeneca)
- For newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who are vulnerable to severe RSV through their second RSV season.
- Vanflyta (Daiichi Sankyo)
- Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive as detected by an FDA-approved test.
- Cyfendus (Emergent BioSolutions)
- Vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis (anthrax) in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
- Ycanth (Verrica Pharmaceuticals)
- Treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.
- Xdemvy (Tarsus Pharmaceuticals)
- Treatment of Demodex blepharitis.
- Balfaxar (Octapharma)
- For the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
- RiVive (Harm Reduction Therapeutics)
- For the emergency treatment of opioid overdose.
- Jemperli (GlaxoSmithKline) New Indication
- In combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
Copyright © 2023 Guideline Central, All rights reserved.